Plus, Olema and Novartis update an agreement for a breast cancer trial, and Roche shares long-term data for Vabysmo in macular edema.
CEPI puts $25M into vaccine for Rift Valley fever:
The Coalition for Epidemic Preparedness Innovation is giving $25.9 million to Wageningen Bioveterinary Research to advance a live-attenuated vaccine for Rift Valley fever into a Phase I/IIa trial. CEPI
said
Tuesday that heavy rain and flooding are linked to outbreaks of the virus, which is primarily spread by mosquitoes in sub-Saharan Africa. “A RVF vaccine will contribute to preparedness for potential virus emergence in yet unaffected regions like Europe,” WBVR’s Paul Wichgers Schreur said in a statement. —
Jaimy Lee